H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers

Overview of attention for article published in Nature Medicine, February 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 18 news outlets
blogs: 2 blogs
policy: 1 policy source
twitter: 104 X users
patent: 10 patents

facebook: 4 Facebook pages
wikipedia: 1 Wikipedia page
f1000: 1 research highlight platform
q&a: 1 Q&A thread

Readers on

mendeley: 419 Mendeley

So far, Altmetric has seen 10 patents that reference this research output.

IMPROVEMENT OF TUMOR IMMUNOGENICITY BY MEANS OF SPLICING-CONTROLLING COMPOUND

Application EP-4400114-A4

European Patent Office

10 Sep 2025

COMPOSITIONS AND METHODS FOR SPLICEOSOME-TARGETED THERAPIES

Application WO-2024119113-A1

World Intellectual Property Organisation (WIPO)

06 Jun 2024

Splice variants associated with neomorphic SF3B1 mutants

Grant US-11761045-B2

United States of America

19 Sep 2023

BIOMARKERS FOR MYELODYSPLASTIC SYNDROME (MDS) AND METHODS OF USING THE SAME

Application WO-2023131866-A1

World Intellectual Property Organisation (WIPO)

13 Jul 2023

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 6 additional patents.